Lupin Ltd — Board/Management Information 2024

Oct 18, 2024

==> picture [79 x 93] intentionally omitted <==

October 18, 2024

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

BSE Limited P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Ref: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’). Sub: Appointment of Senior Management Personnel by WOS

Dear Sir/Madam,

We are pleased to inform you that the Company’s Wholly Owned Subsidiary Lupin Management, Inc., USA has appointed Mr. Claus Jepsen as ‘President, Global Specialty’. Mr. Jepsen shall accelerate Lupin’s plans to evolve its specialty brand business and to attain its mission to bring access to innovative medicines for patients and communities it serves.

Disclosure in compliance with Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of change in Senior Management is enclosed as Annexure - 'A’ .

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED Digitally signed by Amit Kumar Gupta DN: c=IN, o=Personal, title=7875, Amit Kumar pseudonym=d30e6db65d0a41f2b9a52198e78bf149, 2.5.4.20=b7e8678b2d6b381cb8f4761d9cbb4338253df2c8e93e 8fcf768f8e86438a00a1, postalCode=400705, st=Maharashtra, serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d 70287df6aad1994f0b522fa08a, cn=Amit Kumar Gupta Gupta Date: 2024.10.18 21:32:36 +05'30' AMIT KUMAR GUPTA COMPANY SECRETARY (ACS -15754)

Encl: - Annexure - 'A’

LUPIN LIMITED

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

==> picture [79 x 93] intentionally omitted <==

Annexure - 'A’

Particulars as per Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

==> picture [467 x 357] intentionally omitted <==

----- Start of picture text -----

Sl. No. Particulars Description
1. reason for change viz. appointment, Appointment of Mr. Claus Jepsen as Senior Management
re-appointment, resignation, removal, Personnel to be designated as ‘President, Global
death or otherwise. Specialty’ by Lupin Management, Inc., USA, Wholly
Owned Subsidiary of the Company.
2. date of appointment/re-appointment/ October 18, 2024, and is not for a fixed term.
cessation & terms of appointment/
re-appointment.
3. brief profile. Mr. Jepsen has over 30 years of experience in the
pharmaceutical industry, leading commercial strategy,
portfolio choices and launch planning across Europe,
Asia, and the United States.
Mr. Jepsen has worked with Takeda Pharmaceuticals,
where he led the Global Product Strategy for Rare
Diseases. In this role, he spearheaded major initiatives
aimed at bringing new treatments to patients with rare
and often underserved medical needs. Prior to Takeda,
he was at GSK and served in many roles including
country general manager in Asia and led global
franchise management in therapeutic areas such as
Immunology, Respiratory and Neurology. Mr. Jepsen has
launched major brands like Ellipta in the U.S., and has led
brands such as Advair and Seretide in both Europe and
U.S.
4. disclosure of relationships between None
directors.
----- End of picture text -----

LUPIN LIMITED

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com